Shunsuke Iwano/LinkedIn
Jun 23, 2026, 23:30
Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
Shunsuke Iwano, Representative Director and CEO, Head of Regulatory Affars Practice Japan at Eliquent Japan, Inc, shared on LinkedIn:
”PMDA has released a new Early Consideration on the clinical evaluation of Factor VIII and Factor IX products for pediatric congenital hemophilia in Japan.
Key takeaway: PMDA is introducing greater flexibility for pediatric rare disease development.
For hemophilia therapies:
- Patients aged 12 plus can generally be evaluated together with adults
- Under certain conditions, Japanese clinical trials in children under 12 may be waived by leveraging foreign pediatric data
This is an important step toward reducing development burden, minimizing unnecessary pediatric trials, and accelerating access to innovative therapies in Japan.
A meaningful signal that Japan is becoming more pragmatic in rare disease drug development.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?